Chris Steel, leader of PA's Healthcare IT Working Group in the US, was quoted in the May issue of PharmaVoice, in two articles covering electronic medical records.
In the first article, Chris comments on the benefits, such as better trial data and better measurement of drug safety and efficacy, and challenges, i.e. cost and speed to market, that pharmaceutical companies may face from a systemswide, interoperable electronic records system. According to Chris, "EHR (electronic health records)...will support the collation and analysis of data which show the efficacy of different therapies within different patient populations, supporting a more targeted response. Whether this is a benefit or a risk to pharmaceutical companies depends on how early and how effectively they engage as a key player in shaping the change."
In the second article, which covered what the next phase of EMR adoption will mean to the pharmaceutical industry, Chris comments that "pharma will have to get much more closely involved in working with payers and providers to understand what treatment approaches they would like to be able to use over the next five years. This will not replace the current push model of drug development which starts with finding the molecule but complements it with a more patient oriented pull model which might, for example, result in known molecules being delivered as part of different treatment approaches through different devices in different formulations."
To read these two articles, please visit here and turn to pages 12 and 22, respectively.
To visit PA's Heathcare pages, click here.